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Abstract
Hypertensive adults demonstrate decreased performance on neurocognitive testing compared with
that of normotensive controls. There is now emerging, preliminary evidence that children with
hypertension also manifest neurocognitive differences when compared to normotensive controls,
findings postulated to potentially represent early signs of hypertensive target organ damage to the
brain. However, reports in children to date have been limited to database and single-center studies.
We have established an ongoing, prospective, multicenter study of neurocognition in children with
primary hypertension. This article outlines the study methods, with particular attention to the
unique challenges in this area of clinical research. We highlight aspects of the study design that
are specifically designed as solutions to these challenges.
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Introduction
The prevalence of primary hypertension in children has increased significantly, a public
health phenomenon that parallels the current childhood obesity epidemic. School screening
studies show that the prevalence of hypertension is as high as 10% in children who are
overweight, a remarkably high number given that nearly 20% of adolescents in the United
States are obese.(1) The rising prevalence of pediatric hypertension raises concerns about
impaired cardiovascular and other outcomes in adulthood.
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Recent studies suggest that hypertension during childhood may cause harm even during
childhood.(2) Preliminary studies suggest that children with primary hypertension score
lower on measures of neurocognition compared with normotensive controls. In particular,
early findings suggest that hypertensive children have diminished scores in measures of
executive function (EF; higher-order regulatory functions that include attention, inhibitory
control, self-monitoring, planning/problem solving, working memory, and processing
speed).(3,4) , These findings are postulated to potentially represent an early manifestation of
hypertensive target organ damage to the brain.(5) Further study of neurocognition in
children with hypertension is needed to determine the impact of hypertension on the brain
both in childhood and potentially later into adulthood, and to assess the degree to which any
effects can be minimized, or perhaps, reversed.
With funding from the National Institutes of Health, we have established a prospective,
multicenter study of neurocognition in children with primary hypertension. The objective of
this article is to describe the study's methods, with particular emphasis on challenges and
opportunities in designing studies to evaluate cognition in the setting of pediatric
hypertension. This description of methods and challenges should provide guidance to
researchers interested in this area of investigation.
Study Description
Research Aims
The specific aims of the study are to (1) define the impact of primary hypertension on
executive function by comparing results of a comprehensive multimethod assessment of
executive function in hypertensive subjects to results in normotensive controls, and (2)
investigate the reversibility of executive dysfunction by evaluating the effect of
antihypertensive therapy. In order to achieve these aims, both hypertensive and control
subjects complete a baseline (pre-intervention) assessment consisting of laboratory
evaluation and neurocognitive testing. The hypertensive subjects are then treated according
to national consensus guidelines and local standards. After a 12-month period, the same
neurocognitive testing is repeated in both the hypertensive and control subjects. Figure 1
shows the overall study design and Table 1 shows inclusion and exclusion criteria for
hypertensive and normotensive groups.
Sites and Participants
Participating recruitment sites include the University of Rochester (PI, M. Lande), Emory
University (PI, D. Batisky), and Maimonides Medical Center (PI, J. Kupferman). A total of
seventy-five newly diagnosed, untreated hypertensive children aged 10 – 18 years old will
be recruited through the Pediatric Hypertension Clinics at each site. All hypertensive
subjects are required to have clinic BP ≥95th percentile and sustained hypertension
confirmed by 24-hr ambulatory BP monitoring (ABPM). For comparison, 75 normotensive,
healthy 10-18 year old children will be recruited across the three sites from participating
general pediatric and family medicine practices. Control subjects are required to have clinic
BP < 95th percentile and normotension confirmed by ABPM. The control group will be
frequency matched (not individually matched) to the hypertensive group for maternal
education, sex, and proportion with obesity (BMI ≥ 95th percentile) with imbalances in other
potential confounding variables adjusted for in the statistical analysis.
Study Organization
The University of Rochester Medical Center (URMC) serves as Clinical Coordinating
Center (PI, M. Lande). Central laboratory tests are performed by the University of Rochester
Clinical Trials Laboratory. The Steering Committee, comprised by each site PI, the Clinical
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Coordinating Center neuropsychologist (H. Adams), and the study senior neuropsychologist
(S. R. Hooper), meets quarterly. The Safety Committee comprised by the URMC PI, the
director of the Pediatric Clinical Research Office at URMC and the director of the Adult
Hypertension Clinic at URMC meets at least twice a year and additionally as needed.
Study Measures and Procedures
ABPM—Study ABPM procedures follow published American Heart Association
guidelines,(6) utilizing the Spacelabs 90217 oscillometric monitor. Blood pressure
measurements are recorded every 20 minutes for the entire 24-hr period, and daytime and
sleep periods are determined by patient diary. A minimum of 40 total readings, including at
least 5 readings during sleep, are required for the study to be considered valid. BP load is
defined as the percentage of readings above the 95th percentile for ambulatory norms in the
24-hr period. For the hypertensive subjects to be included, they must have sustained
ambulatory hypertension, defined as mean day or night SBP or DBP ≥95th percentile for
ambulatory norms. A hypertensive subject can also be included if the mean ambulatory BP
is < 95th percentile, but the subject has both BP load > 25% (ambulatory prehypertension)
and left ventricular hypertrophy (LVH) on echocardiogram. Control subjects are required to
have both mean SBP and DBP < 95th percentile and BP load < 25% to be included.
Echocardiography—Echocardiography is performed in the hypertensive subjects prior to
the baseline visit and read centrally at the University of Rochester. Control subjects do not
have echocardiography since they are not expected to have cardiac hypertrophy secondary to
increased BP. Left ventricular mass indexed to height2.7 is determined by the area-length
method according to standards published by the American Society of Echocardiography.
Left ventricular hypertrophy is defined as left ventricular mass index (LVMI) ≥ the 95th
percentile for age and sex.(7)
Baseline Laboratory Evaluation—Both hypertensive and control subjects receive
central laboratory evaluations including fasting lipid profile, insulin level, glucose and wide
range CRP at the baseline assessment, due to the potential effects of hyperlipidemia,(8)
insulin resistance,(9) and inflammation(10) on cognition.
Neurocognitive Test Battery—Previous studies show that both adult and pediatric
hypertensive groups are particularly distinguished from non-hypertensive groups by
performance on tasks of executive function (EF). Our pilot study also found decreased EF
skills in hypertensive children, compared to normotensive controls, on parental behavior
ratings of EF in everyday settings.(5,8) Consequently, the current, expanded neurocognitive
test battery was selected to evaluate EF in depth by including both performance-based
laboratory measures and behavioral rating scales. The laboratory measures include direct
tests of problem solving/planning, set-shifting, response inhibition, vigilance, and working
memory, in order to assess components of EF defined in the Pennington and colleagues'
theoretically-derived EF model (Table 2).(11,12) Defined globally as “the ability to maintain
an appropriate problem solving set for attainment of a future goal,”(13) executive functions
in Pennington's model incorporate ‘process’ skills such as self-monitoring/self-regulating
behavior, set-shifting, planning, working memory, and processing speed, and also emphasize
“context specific action selection”(11) which refers to the ability to appropriately select the
correct strategy or response for the task at hand. The neurobiological substrate for this model
is the prefrontal cortex which with its rich interconnections receives and integrates
information from cortex, subcortex, and even brainstem sites. Since the neurocognitive test
battery is not intended for clinical use, the test results are shared with parents only after the
subject has completed the study, and only if specifically requested by the parent.
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Executive Function Assessment – laboratory measures: 1. CogState is a computerized
battery of tests;(14,15) selected EF measures from CogState are used in the present study.
1a. CogState Groton Maze Learning evaluates problem solving, cognitive flexibility, and
nonverbal/visual learning. Subjects use trial-and-error strategies to learn a maze pattern over
multiple learning trials. 1b.CogState Set Shifting is a task of concept formation and
cognitive flexibility. Subjects must recognize and adapt to changing rule sets, using
feedback from their own task performance to test and confirm hypotheses. 2. The Conners'
Continuous Performance Test-II (CPT-II)(16) is a computerized test that provides measures
of inattention, impulsivity, and response time. Subjects must respond when specific stimuli
are presented on the computer screen, but inhibit this prepotent response when other stimuli
appear. 3. Digit Span and Spatial Span (Wechsler Intelligence Scale for Children; WISC-IV-
Integrated);(17) these tasks evaluate auditory and visual working memory, respectively.
Subjects must repeat number sequences or copy manual sequences exactly; these are each
followed by the more challenging working memory task of copying sequences in reverse
order. 4. The Delis-Kaplan Executive Function System (D-KEFS) Tower Test is a measure
of planning and problem-solving abilities.(18) Subjects must rearrange a stack of disks, in
ascending size, based on models provided by the examiner. Movements are restricted along
three pegs on which the disks are stacked, and specific rules limit subjects' movement of the
disks from one peg to another (e.g., move only one piece at a time). The test assesses the
subjects' ability to plan and execute an effective strategy in the shortest time, and with the
fewest number of moves possible.
Executive Function Assessment – behavior rating scales: As noted above, the initial pilot
study utilized the parent-report version of the Behavior Rating Inventory of Executive
Function (BRIEF). The BRIEF evaluates EF within real-world settings.(19) The current
study extends the assessment of EF in day-today life with addition of the self-report and
teacher-based BRIEF ratings. This strategy yields multi-informant data, using cross-
validated measures, on subject's day-to-day EF behaviors such as organization and planning
of homework and chores, the ability to sustain attention in class, or to navigate shifts
between activities or cognitive tasks. BRIEF scores are norm-referenced to provide
information on EF performance in comparison to same-age peers.
Assessment of other cognitive domains: In addition to EF measures, the neurocognitive
test battery includes direct assessments of verbal learning (Rey Auditory Verbal Learning
Test, RAVLT) and fine motor dexterity (Grooved Pegboard), based on prior evidence that
children with hypertension may have diminished capacity in these cognitive domains in
comparison to their normotensive peers.(20,21) On the RAVLT, participants learn and recall
a list of words presented over multiple learning trials.(22) Primary measures include list
recall both in the short-term after the final learning trial, and again after a delay. The
Grooved Pegboard test evaluates dominant and non-dominant hand fine-motor dexterity and
speed.(22) Subjects use their fingertips to rapidly fit metal, “key”-shaped pegs into a matrix
of holes. Finally, the direct neurocognitive evaluation includes an estimate of general
intellectual function using the two-subtest version of the Wechsler Abbreviated Scales of
Intelligence (WASI; Vocabulary, Matrix Reasoning).(23) This enables us to examine
whether imbalances exist across hypertensive and normotensive groups with regard to global
cognitive ability so as to lessen the effects of the level of cognitive ability on response to the
antihypertensive treatment.
Results from our pilot studies show that children with both hypertension and obesity were at
risk for clinically significant elevations in anxiety and depression symptoms.(3) The
relationship between anxiety and hypertension has also long been reported in adult studies.
(24) Therefore, in the current study, we continued to evaluate mood function in hypertensive
children and the normotensive control group. In that regard, behavioral rating scales of
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mood state (anxiety, depression) and general behavioral function are administered. Mood
symptoms are evaluated with the child self-report measures of the Multidimensional Anxiety
Scale for Children (MASC),(25) and the Child Depression Inventory (CDI).(26) The Child
Behavior Checklist (CBCL) provides additional parent-based assessment of the child's
mood, and other behavioral concerns such as social difficulties, attention problems,
noncompliance/defiance, and aggression.(27)
Because daytime sleepiness and sleep disorders are also associated with cognitive
dysfunction in both adults and children,(28,29) we also administer the Sleep-Related
Breathing Disorder scale of the Pediatric Sleep Questionnaire (PSQ)(30). This survey is
completed by parents to estimate disordered sleep overall; subjects are also asked to report
number of hours of sleep they had received the night prior to neurocognitive testing as an
estimate of sleepiness that day.
Standardized Antihypertensive Therapy—The study evaluates for changes in EF and
related cognitive functions after 1 year of treatment that the hypertensive patient would
normally receive according to local standard of care and national consensus guidelines.(2)
Thus, the primary focus is on the effectiveness of intervention in a real-world setting; the
efficacy of antihypertensive treatment is already well established in prior investigations.(31)
For the hypertensive subjects, antihypertensive treatment (lifestyle modifications and/or
medication) begins after completion of the baseline laboratory and neurocognitive
assessments. For subjects with stage 1 hypertension without LVH, antihypertensive
medication is started after three months if there is no improvement with lifestyle
modification, or is started immediately in subjects who have previously failed a concerted
effort at lifestyle modification, at the discretion of the treating site investigator. Subjects
with stage 2 hypertension or LVH are started immediately on antihypertensive medication.
When antihypertensive medication is indicated, the initial drug is lisinopril. Angiotensin
converting enzyme inhibitors are the most commonly prescribed class of antihypertensive
medication prescribed by pediatric nephrologists for the treatment of primary hypertension,
(32) and they are commonly used by the investigators at the participating sites. Female
subjects of child bearing potential and their parents are counseled on the potential
teratogenic risks of ACE inhibitors. Urine pregnancy tests are performed prior to initiating
ACE inhibitor therapy and then every 3 months for the duration of the study. Blood
chemistry measures for potassium and creatinine are performed within 4 weeks of starting
lisinopril. Thiazide diuretics are used as second-line agents, if needed, except for
competitive athletes, who receive amlodipine as a second-line agent. Amlodipine is also
used for subjects who do not tolerate lisinopril.
Once antihypertensive medication is initiated, subjects are seen every 4 – 6 weeks through
the site's Pediatric Hypertension clinic to have their therapy titrated until adequate control of
hypertension is achieved (casual BP < 95th percentile). Initial dosing of antihypertensive
medication and subsequent dose adjustments are at the discretion of the site investigator.
Once adequate control is achieved, the hypertensive subjects are followed every 3 months to
monitor BP control and adjust antihypertensive therapy accordingly. Subjects achieving BP
control with life style modification alone are followed every 3 months throughout the course
of the study. Upon enrollment, the subjects are given a home digital BP monitor (OMRON
BP760) to measure their home BP once daily in the week prior to their next visit. The
subjects keep a log of these measurements, which is then brought to all visits to help
determine the response to therapy. All hypertensive subjects meet with a nutritionist at the
beginning of the study and again at 3 - 6 months to review the Dietary Approaches to Stop
Hypertension (DASH) diet,(33) salt restriction, and if needed, weight loss counseling.
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The primary outcome is comparison of neurocognitive performance of hypertensives and
controls at the baseline assessment. Seventy-five subjects per group provides 80% power to
detect an effect size of 0.46 for baseline differences in the BRIEF Global Executive
Composite, based on data from the pilot study.(3) Multivariate analyses will be adjusted for
group imbalances in age, sex, maternal education, household income, race/ethnicity, IQ,
obesity, hyperlipidemia, insulin resistance, inflammation, measures of anxiety and
depression, disordered sleep, and hours of sleep the night prior to neurocognitive testing. In
addition, all of the cognitive measures used are age-normed, providing standard metrics for
evaluation of these data in relation to age-expected performance. Comparison of the
hypertensive and control subjects at baseline will be done with and without the hypertensive
subjects enrolled with ambulatory prehypertension but also LVH, since these subjects do not
meet the American Heart Association definition of ambulatory hypertension.(6)
Performance of hypertensive subjects on neurocognitive testing after 1 year of
antihypertensive therapy will be compared to their own baseline performance prior to
antihypertensive therapy. Pre-post analysis will also be performed for the normotensive
control subjects to estimate any practice effect or improvement with age. Within the
hypertensive group, the correlation between the neurocognitive measures and systolic and
diastolic ABPM parameters (including BP standard deviation as a measure of variability)
will be determined. To further test the hypothesis that more severe hypertension is
associated with greater reductions in cognitive function, we will also compare cognitive
function between the hypertensive subjects with versus without LVH at the baseline
assessment. Finally, among the hypertension subjects, the correlation between improvement
in BP and improvement in neurocognition over the 12-month study period will be examined,
adjusting for the duration of BP control (< 95th percentile) within the 12-month treatment
period, estimated by interim clinic and home BP measurements.
Challenges, Threats to Validity, and Solutions
Challenge #1 – Potential Confounders—Hypertensive-associated reductions in
neurocognitive test performance tend to be relatively small in magnitude, and absolute
scores fall within the broad developmentally normal range.(5,8) Such findings may be
overshadowed by subject characteristics that are known to more strongly influence
performance on tests of cognition, such as socioeconomic status, depression, and anxiety.(8)
In addition, a surprisingly high percentage of children referred for elevated BP have the
diagnosis of a learning disability and/or attention deficit disorder,(34) both pathophysiologic
processes that may strongly influence performance on neurocognitive testing and therefore
overshadow any potential effect of hypertension. Furthermore, maternal education level can
strongly influence performance on neurocognitive measures in children.(35) In addition,
many children with hypertension are obese, an entity associated with metabolic syndrome,
disordered sleep, and obstructive sleep apnea which are themselves associated with
neurocognitive dysfunction.(9,30) Finally, subject engagement with neurocognitive testing
is essential. Critical neurocognitive test data can be lost when subjects are not well-rested on
the day of examination, a particular challenge in studies involving adolescent participants.
Table 3 lists the solutions incorporated into the study design in order to prevent these
potential confounders from overshadowing any difference between groups attributable to
hypertension.
Challenge #2 – How to develop measurement for small effect sizes?—In order
to detect the likely subtle between-group difference, the study ensures that the BP level of
the groups is as distinct as possible by requiring ABPM confirmation of both hypertension
and normotension. Individuals with pre-hypertension (except those with LVH) or white-coat
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hypertension by ABPM are excluded. Hypertension subjects will have had a variable
number of elevated BP readings documented in the primary care office prior to referral. For
initial consideration for the study, they are also required to have hypertension clinic BP
≥95th percentile. By contrast, the control subjects are considered for recruitment for the
study based on only one BP reading in the primary care office. However, the strict definition
of ambulatory normotension, using both normal mean BP and also normal BP load should
help prevent misclassification of BP category of the control subjects.
In addition, the neurocognitive test battery is designed to maximize the likelihood of
detecting a relatively small effect size. Specifically, the CPT-II and CogState tasks, all
computer-administered, enable precise measurement of response time, down to the
millisecond, a feature that is especially desirable for evaluating potentially subtle differences
between hypertensive and normotensive groups and also subtle changes within subjects over
time. The computerized neurocognitive assessment data may detect small effects but have
less relevance for every-day settings; therefore we have also included parent, child, and
teacher-based questionnaires that evaluate executive function with high ecological validity
(i.e., Behavior Rating Inventory for Executive Function).
Challenge #3 – How to handle practice effects and developmental changes?—
Repeated administration of neurocognitive testing, such as before and after antihypertensive
therapy, can be confounded by practice effects - the propensity for scores to improve by
virtue of learned strategies or recall of task content from repeated test administration. This is
a particularly common problem with repeat administration of standard tests of EF that often
depend on novelty. Furthermore, test scores may improve with age, and repeated testing
may yield improved scores due to regression to the mean. The study design incorporates
several deliberate strategies to minimize the magnitude of practice effects and the effects of
age:
1. All of the cognitive measures used are age-normed, providing standard metrics for
evaluation of these data in relation to age-expected performance, and age is
included as a covariate in the statistical analysis.
2. We wait a full 12 months to re-administer the test battery, thereby diminishing
improvement due to retention of learned strategies or recall of task content.
3. CogState tasks were selected, in part, because the battery was designed for repeated
assessments using alternate forms, thus minimizing practice effects.(36)
4. The use of a contemporaneous, well-matched control group that also completes re-
assessment after 12 months, permits estimation of, and adjustment for (if needed)
potential practice effects and age-expected changes in test performance,
independent of change attributable to antihypertensive therapy.
Challenge #4 – How to most ethically assess for the effect of antihypertensive
treatment on cognition?—We have not proposed a randomized clinical trial in which
half of the hypertensive subjects receive antihypertensive medication and half receive
placebo. While a randomized trial would have advantages, it would have meant excluding an
essential group of subjects: those with stage 2 hypertension and those with LVH, since
standard of care is to treat all such children with antihypertensive medication upfront.(2) In
our pilot study, children with severe ambulatory hypertension and those with LVH at
baseline were the subjects most likely to have improvement in executive function with
antihypertensive therapy,(4) a finding that underscores the importance of not excluding
these subjects from the current study. Furthermore, a randomized controlled trial would have
meant giving placebo to some hypertensive children for a full year, even those children who
have already made an earnest attempt at therapeutic lifestyle modification without success.
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While use of placebo is considered justifiable in pediatric antihypertensive drug trials, it is
recommended that the duration of placebo use be limited to 4 to 8 weeks.(37) A randomized
clinical trial with such a short duration would significantly increase the risk of practice
effect on the neurocognitive measures and might not allow enough time for blood pressure
control or cognitive improvement. Therefore, the reversibility of hypertension-associated
neurocognitive deficits in the current trial is assessed by comparing each hypertensive
subject to him or her self, before and after standard of care treatment.
An additional challenge is the inevitable variation in treatment compliance from subject-to-
subject and also within the same subject over the course of a year. In the current study, the
importance of adherence to antihypertensive medication and lifestyle modification is
emphasized to the subject at each interim visit. Furthermore, to account for the variability in
compliance and response to therapy, the statistical analysis will_adjust for the duration of
BP control (< 95th percentile) within the 12-month treatment period, estimated by the
interim clinic and home BP measurements.
Lastly, for patients treated with lisinopril, the current study design will not distinguish
whether any improvement in cognition was due to the BP lowering effects of the lisinopril
or to a direct effect of the drug itself. If improvement in cognition is demonstrated, then
future research can compare the effect of different antihypertensive drug classes, including
ACE inhibitors with differing levels of central nervous system penetration.(38)
Challenge #5 – How to ascertain and maintain the matched sample?—The
hypertensive subjects are recruited from referrals to the Pediatric Hypertension Clinics at
each participating site. Control subjects are recruited from participating general pediatric
and family medicine practices. Parents of potentially eligible control children are contacted
with a letter sent by their primary care provider, and directed to contact the study
coordinator if interested in the study. In order to ensure appropriate matching to the
hypertensive group, the study coordinator assesses maternal education and screens for
exclusion criteria by telephone, when contacted by the parents of prospective subjects.
Potential control subjects who meet the targeted matching criteria (maternal education,
obesity, age) are then enrolled. Site investigators are responsible for ongoing monitoring of
the demographic characteristics of the enrolled subjects at their sites in order to ensure
balance of matching criteria among hypertensive and control subjects. The PI and Steering
Committee are responsible for oversight of monitoring of the demographics of enrolled
subjects in the study as a whole. Demographic characteristics of enrolled hypertensive and
control subjects are reviewed at each meeting of the Steering Committee so that adjustments
can be made as needed to future enrollment targets in order to maintain balance of the
matching criteria between groups. This also will help any future adjustments needed
secondary to dropouts from the study and subject noncompliance.
In order to maximize retention of the study population, subjects receive reminder phone
calls prior to each scheduled visit. Hypertensive subjects who miss treatment visits are
contacted immediately to assure prompt rescheduling of the visit. Updated contact
information is obtained during each follow-up visit for the hypertensive subjects and
quarterly by phone for the control subjects. Lastly, subject honoraria are paid for both the
baseline and 1-year neurocognitive assessment visits.
Challenge #6 - How to address issues of quality control and site
communication?
Quality control of the neurocognitive data: The neurocognitive test battery is
administered by a child neuropsychologist or a graduate psychology trainee under direct
supervision of a neuropsychologist at each site. All neuropsychological examiners are
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blinded to the subject's BP status. The URMC clinical coordinating center neuropsychologist
(H Adams) reviews the first 5 cases completed from each participating site and then
subsequently reviews a random selection of 20% of the cases from all 3 sites. These audits
are conducted to verify administration fidelity and to perform double scoring of the protocol
procedures. Double scoring ensure that raw score points are accurately awarded and are
accurately transformed into age-adjusted standardized scores, and that no transcription errors
occur from source documents to study case report forms. The senior study
neuropsychologist (S Hooper) will review a random selection of 20% of the cases
administered by the URMC neuropsychologist.
Quality control of the treatment protocol: The decision to initiate antihypertensive
medication and timing and magnitude of dosing adjustments is entrusted to the treating site
investigator, within the general guidelines of the study protocol with regard to choice of
medication (first line, lisinopril), frequency of follow up visits, and treatment goals (clinic
BP < 95th percentile). To monitor adherence to these general guidelines, the clinical
coordinating center monitors the frequency of interim treatment visits at the participating
sites. Home and interim visit BP measurements and antihypertensive medication
adjustments are reported to the clinical coordinating center after each interim visit.
Site communication: The clinical coordinating center study coordinators and PI are
available to the participating sites on a daily basis, as needed. Conference calls between the
clinical coordinating center and the individual participating sites take place at least monthly,
in order to review recruitment progress, study procedures, and any problems as they arise.
Annual meetings of the study personnel occur at the Coordinating Center.
Summary
The main objectives of this ongoing, multi-center study are to determine the impact of
primary hypertension on neurocognition in children and whether these effects are reversible
with treatment of hypertension. In this technical review, we have summarized the design and
methods of the study, and shared the unique challenges that exist in assessing subtle changes
in neurocognition, reflecting potential hypertension-associated target organ damage of the
pediatric brain; we have also discussed real, concrete solutions to these unique challenges
that are applicable to the clinicians, teacher, and researcher.
Translational studies such as this are critical to determine what BP levels result in brain
target organ effects, both in childhood and adolescence and potentially later into adulthood.
Clarification of the detrimental effects of hypertension during childhood will help in the
development of improved treatment guidelines targeted at the children most at risk for poor
cardiovascular outcomes later in life. It is essential for those engaged with this population to
pay careful attention to the myriad of challenges that could affect the results of a treatment
trial as these challenges can affect the care of children with hypertension.
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Figure 1. Study design
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Table 1
Inclusion and exclusion criteria
Inclusion
Age 10 to 18 y
Primary hypertension
English speaking (required for the neurocognitive assessments)
Clinic SBP and/or DBP ≥ 95th percentile




Previous or current treatment with antihypertensive medication
Learning disability (Individual Education Plan or Section 504 Plan at school)
Treatment with medication for inattention
Disorder of cognitive function, seizure disorder, or history of severe head injury (loss of consciousness > 30 min)
History of chronic disease
Previous chelation treatment for elevated lead level
Previous sleep study diagnosis of obstructive sleep apnea
Pregnancy or breastfeeding
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